$4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked warrants Altamira Therapeutics Ltd. (“Altamira” or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback